Total buying$00 buys
ADPT
Adaptive Biotechnologies Corp
NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Insider activity for last month from 09/20 to 10/20.
How these metrics are calculated
Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total selling$4.73M23 sells
Net open-market−$4.73MBuying minus selling
Active insiders3Distinct reporting owners
Insider activity report
Calendar-month buckets within the selected date range
Latest filing: Oct 16, 2026
Open-market transaction mix · 23 transactions in the selected period
Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.
View exact monthly counts and disclosed values
| Month | Buys | Sells | Awards (A) | Buy value | Sell value | Net P/S value |
|---|---|---|---|---|---|---|
| Sep 2026 | 0 | 0 | 0 | $0 | $0 | $0 |
| Oct 2026 | 0 | 23 | 0 | $0 | $4.73M | -$4.73M |
Distinct insiders active
Reporting-owner CIKs by month · peak Oct 2026 (3)Sep 2026Oct 2026
Largest insider activity
By absolute net disclosed value · current transaction page- RJ-$573.9k
- BS-$193.3k
ADPT transaction history
Newest filings · 20 transactions per pageLatest insider transactions
Form 4 filings from last month.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
ADPTAdaptive Biotechnologies Corp | Rubinstein JuliePRES | M · exercise10b5-1 detectedSEC filing ↗ | $144kView disclosure → | |
ADPTAdaptive Biotechnologies Corp | Rubinstein JuliePRES | M · exercise10b5-1 detectedDerivative securitySEC filing ↗ | $0View disclosure → | |
ADPTAdaptive Biotechnologies Corp | Rubinstein JuliePRES | M · exercise10b5-1 detectedDerivative securitySEC filing ↗ | $0View disclosure → | |
ADPTAdaptive Biotechnologies Corp | Rubinstein JuliePRES | M · exercise10b5-1 detectedDerivative securitySEC filing ↗ | $0View disclosure → | |
ADPTAdaptive Biotechnologies Corp | Rubinstein JuliePRES | S · sale10b5-1 detectedSEC filing ↗ | -$304kView disclosure → | |
ADPTAdaptive Biotechnologies Corp | Rubinstein JuliePRES | M · exercise10b5-1 detectedSEC filing ↗ | $144kView disclosure → | |
ADPTAdaptive Biotechnologies Corp | Rubinstein JuliePRES | S · sale10b5-1 detectedSEC filing ↗ | -$313kView disclosure → | |
ADPTAdaptive Biotechnologies Corp | Rubinstein JuliePRES | M · exercise10b5-1 detectedSEC filing ↗ | $144kView disclosure → | |
ADPTAdaptive Biotechnologies Corp | Rubinstein JuliePRES | S · sale10b5-1 detectedSEC filing ↗ | -$15.2kView disclosure → | |
ADPTAdaptive Biotechnologies Corp | Rubinstein JuliePRES | S · sale10b5-1 detectedSEC filing ↗ | -$26.7kView disclosure → | |
ADPTAdaptive Biotechnologies Corp | Rubinstein JuliePRES | S · sale10b5-1 detectedSEC filing ↗ | -$31.0kView disclosure → | |
ADPTAdaptive Biotechnologies Corp | Rubinstein JuliePRES | S · sale10b5-1 detectedSEC filing ↗ | -$256kView disclosure → | |
ADPTAdaptive Biotechnologies Corp | Rubinstein JuliePRES | M · exercise10b5-1 detectedSEC filing ↗ | $144kView disclosure → | |
ADPTAdaptive Biotechnologies Corp | Bobulsky SusanCCO · MRD | S · sale10b5-1 detectedSEC filing ↗ | -$193kView disclosure → | |
ADPTAdaptive Biotechnologies Corp | Rubinstein JuliePRES | M · exercise10b5-1 detectedDerivative securitySEC filing ↗ | $0View disclosure → | |
ADPTAdaptive Biotechnologies Corp | Rubinstein JuliePRES | M · exercise10b5-1 detectedDerivative securitySEC filing ↗ | $0View disclosure → | |
ADPTAdaptive Biotechnologies Corp | Rubinstein JuliePRES | M · exercise10b5-1 detectedDerivative securitySEC filing ↗ | $0View disclosure → | |
ADPTAdaptive Biotechnologies Corp | Rubinstein JuliePRES | S · sale10b5-1 detectedSEC filing ↗ | -$153kView disclosure → | |
ADPTAdaptive Biotechnologies Corp | Rubinstein JuliePRES | S · sale10b5-1 detectedSEC filing ↗ | -$193kView disclosure → | |
ADPTAdaptive Biotechnologies Corp | Rubinstein JuliePRES | M · exercise10b5-1 detectedSEC filing ↗ | $144kView disclosure → |
Filing-only signals
Deterministic matches in the selected period
Filing detail checks
Secondary metrics for the selected periodTransaction codes
By Form 4 transaction code in selected period53transactionstxns
- M · Option exercise · dominant30 · 57%
- S · Open-market sells23 · 43%
Activity by reported role
A joint filing can contribute to multiple rolesPRES44
CPO8
CCO1
MRD1
Reported Holdings After
Separated by insider, security, and ownership type
Rubinstein JulieCommon Stock · Direct
377,802Oct 16, 2026
Rubinstein JulieStock Option (right to buy) · Direct
237,205Oct 16, 2026
Lo FrancisCommon Stock · Direct
220,867Oct 01, 2026
Lo FrancisStock Option (right to buy) · Direct
93,765Oct 01, 2026
Bobulsky SusanCommon Stock · Direct
389,350Oct 06, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells redSep 20 → Oct 20
LessMore
Adaptive Biotechnologies Corp Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Adaptive Biotechnologies Corp?
RUBINSTEIN JULIE, BOBULSKY SUSAN, LO FRANCIS.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Rubinstein Julie reported a sale on Oct 16, 2026 valued at $7.63k. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $4,730,794.33. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.